TMCnet News

BioHiTech Global Reports Third Quarter 2020 Financial Results
[November 19, 2020]

BioHiTech Global Reports Third Quarter 2020 Financial Results


CHESTNUT RIDGE, N.Y., Nov. 19, 2020 /PRNewswire/ -- BioHiTech Global, Inc. ("BioHiTech" or the "Company") (NASDAQ: BHTG), a sustainable technology and services company, today announces financial results for its third quarter 2020 ended September 30, 2020.

Third Quarter Highlights:

  • Announced that Carnival Corp., the world's largest cruise company, reinitiated its installation program of the BioHiTech's Revolution Series Digesters aboard its ships in preparation for the eventual resumption of cruising
  • Announced a total of $1.4 million in new food waste digester purchase orders for its Revolution Series Digesters from Carnival Corp. as part of its previously announced purchase contract between the two companies with an estimated value of up to $14 million
  • Received first Altapure AP-4™ disinfectant systems purchase contract from Hazelton Area School District in Pennsylvania to protect its schools against COVID-19 and other viral infections
  • Shipped the first Altapure AP-4™ disinfectant system to the cruise industry where it will be installed on the SeaDream I yacht, a mega-yacht boutique ship
  • Closed an $9.5 million (gross) underwritten public offering, including the underwriter's over-allotment, with net proceeds of $8.4 million to the Company

Developments Subsequent to the End of the Third Quarter

  • Appointed Anthony Fuller as Chief Executive Officer
  • Received contract to install seven new food waste digesters at various Hackensack Meridian Health healthcare facility locations
  • Made strategic investment in Rensselaer, NY land venture as a material step to establishing a renewable energy campus, including New York state's first waste conversion facility
  • Announced a total of $1.9 million in new food waste digester purchases, bringing total orders received from Carnival Corp. for the Company's Revolution Series™ food waste digesters to $3.3 million, including $600,000 in digester orders from Princess Cruises, since Carnival reinitiated the installation of digesters on its ships in July 2020

"While the third quarter fell short of our expectations financially, a number of significant events during the quarter and after September 30 provide reasons to believe better quarters are ahead," commented BioHiTech's CEO Anthony Fuller.  "Carnival Corp. has placed $3.3 million worth of food waste digesters orders since July, providing what we believe is an incredible testimony to our technology and ability to solve real-world food waste problems for the travel and hospitality industry.  Additionally, our multi-unit order for food digesters from the Hackensack Meridian Healthcare system provides further validation for our Revolution Series Digesters that convert food waste into a liquid that can be safely discharged through any standard sewer line.

"The Altapure AP-4 disinfectant system saw initial deployments in a school district as well as on a cruise ship, and we are confident it can address future needs across a range of industries, all of which have been affected by COVID-19.  We continue to ascend the learning curve of operating our Martinsburg, W.V. plant using our patented High Efficiency Biological Treatment ("HEBioT") process. In many ways, are still in the commissioning phase with this plant.  We've made notable changes and are pleased with the progress we are seeing.  Our learnings from the Martinsburg facility will prove vital as we progress towards our potential development of a 'renewable energy campus' planned for Rensselaer, N.Y.  Quite simply, BioHiTech provides cost-effective technology solutions for sustainable waste management, whether on a large scale like our Martinsburg resource recovery facility or on a smaller scale via our food waste digesters.

"As we look ahead to 2021 and beyond, and as the newly appointed CEO, we are setting course with enhanced corporate initiatives. These initiatives are designed to maximize shareholder value and help investors better measure our progress moving forward.  I've laid out five goals on which we are focused heading into 2021:  1) increase revenue appreciably, 2) reduce SG&A meaningfully, 3) improve the plant operations measurably, 4) tell the story clearly, and 5) function as a team effectively.  I look forward to elaborating more on these goals in our earnings conference call later this afternoon and throughout the quarter," concluded Mr. Fuller.

Financial Highlights for Q3 2020

Revenues: Total revenue in the third quarter of 2020 was $742,877, a decrease of 48% compared to revenue of $1,426,775 in the third quarter of 2019.  Third quarter revenue decreased primarily due to a reconfiguration process conducted at the Martinsburg (W.V.) High Efficiency Biological Treatment (HEBioT) facility during the quarter by the facility's new management team that temporarily reduced production and caused its revenue to decline by 59% year-over-year to $248,274 prior to a $247,649 negative adjustment in previously estimated take-or-pay contract revenue.  Rental, service, and maintenance revenue declined 13% from $489,555 in the third quarter of 2019 to $423,996 in the third quarter of 2020.  Equipment sales partially offset the declines in the HEBioT and rental, service, and maintenance revenue and rose 370% from $62,565 in the third quarter of 2019 to $293,876 in the third quarter of 2020 due to purchases from Carnival Cruise Lines under their master purchase contract.  Furthermore, management advisory and other fees derived support for Gold Medal, a related entity, decreased from $264,750 in the third quarter of 2019 to $24,380 in the third quarter of 2020 in order for management to devote more focus to the Company's core services.

Operating Expenses: Total Operating Expenses, including $1,256,477 in cost of goods sold and a $917,420 impairment expense at the Martinsburg waste facility, in the third quarter increased 53% from $3,042,020 in the third quarter of 2019 to $4,660,333 in the third quarter of 2020.  Increased production expenses, the aforementioned impairment expense, stock-based compensation, legal and social media expenses, insurance costs at the HEBioT facility, Directors and Officers insurance, and management transition expenses at the HEBioT facility primarily drove the increased operating expenses from the comparable period in 2019.

Loss from Operations: The loss from operations increased from ($1,615,245) in the third quarter of 2019 to a loss of ($3,917,456) in the third quarter of 2020. 

Net Loss: Net loss per share in the third quarter of 2020 was ($0.16) on 22.0 million weighted average shares outstanding, compared to a net loss of ($0.13) per share on 15.6 million weighted average shares outstanding in third quarter of 2019.

Cash: Unrestricted cash at September 30, 2020 was $4,950,112 following an underwritten public offering completed during the third quarter that netted the Company $8,437,480 in proceeds, including the underwriter's over-allotment. 

Earnings Conference Call

Management will host a conference call at 4:30 p.m. ET on Thursday, November 19, 2020 to review financial results and provide an update on corporate developments.  Following management's formal remarks, there will be a question and answer session.

Participants are asked to pre-register for the call via the following link:
https://dpregister.com/sreg/10150010/dd340fff34

Please note that registered participants will receive their dial-in number upon registration and will dial directly into the call without delay.  Those without Internet access or who are unable to pre-register may dial in by calling 1-866-652-5200 (domestic) or 1-412-317-6060 (international).  All callers should dial in approximately 10 minutes prior to the scheduled start time and ask to be joined into the BioHiTech Global call.

The conference call will be available through a live webcast found here:
https://services.choruscall.com/links/bhtg201116.html

It will also be broadcast live through the Company's website with the following link:
http://investors.biohitechglobal.com/events-and-webcasts

A webcast replay of the call can be accessed through the above links and will be available approximately one hour after the end of the call through February 19, 2021.  The call replay can also be accessed by calling 1-877-344-7529 (domestic) or 1-412-317-0088 (international) and using access code 10150010.  The telephonic replay of the call will be available through November 30, 2020.

About BioHiTech Global
BioHiTech Global, Inc. (NASDAQ: BHTG), is a technology services company focused on providing cost-effective solutions that improve environmental outcomes. Our technologies for waste management include the patented processing of municipal solid waste into a valuable renewable fuel, biological disposal of food waste on-site, and proprietary real-time data analytics tools to reduce food waste generation. When used individually or in combination, our solutions lower the carbon footprint associated with waste transportation and can reduce or virtually eliminate landfill usage. In addition, we distribute a patented technology that achieves high-level disinfection of spaces such as classrooms, hotel or hospital rooms and other enclosed areas to combat the spread of viruses and bacteria without the use of harsh chemicals. Our unique solutions enable businesses, educational institutions and municipalities of all sizes to solve everyday problems in a smarter and more cost-effective way while reducing their impact on the environment. For more information, please visit www.biohitech.com.

Forward Looking Statements
Statements in this press release contain certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended. Without limiting the foregoing, words such as "anticipate," "believe," "continue," "could," "estimate," "expect," "explore," "evaluate," "intend," "may," "might," "plan," "potential," "predict," "project," "seek," "should," or "will," or the negative thereof or other variations thereon or comparable terminology. These forward-looking statements are only predictions and involve known and unknown risks and uncertainties, many of which are beyond the Company's control. These statements are also based on many assumptions and estimates and are not guarantees of future performance. These statements are estimates, based on information available to management as of the date of this release, and are subject to further changes. These statements may involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of BioHiTech Global, Inc. to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. BioHiTech Global, Inc. assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future in these forward-looking statements.  Our actual results may differ materially from the results anticipated in these forward-looking statements due to a variety of factors, including, without limitation those set forth as "Risk Factors" in our filings with the Securities and Exchange Commission ("SEC"). There may be other factors not mentioned above or included in the BioHiTech's SEC filings that may cause actual results to differ materially from those projected in any forward-looking statement. BioHiTech Global, Inc. assumes no obligation to update any forward-looking statements as a result of new information, future events or developments, except as required by securities laws.

Company Contact:
BioHiTech Global, Inc.
Richard Galterio
Executive Vice President
Direct: 845.367.0603
rgalterio@biohitech.com
www.biohitech.com
Investors: 
ir@biohitech.com

 





BioHiTech Global, Inc. and Subsidiaries

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)




Three Months Ended September 30,



Nine Months Ended September 30,




2020



2019



2020



2019


Revenue













HEBioT (related party)


$

625



$

609,905



$

1,383,656



$

886,947


Rental, service and maintenance



423,996




489,555




1,251,122




1,426,193


Equipment sales



293,876




62,565




616,992




137,799


Management advisory and other fees
(related party)



24,380




264,750




124,380




761,750


Total revenue



742,877




1,426,775




3,376,150




3,212,689


Operating expenses

















HEBioT processing



945,810




786,680




2,778,514




1,309,176


Rental, service and maintenance



139,665




176,651




552,195




508,164


Equipment sales



171,002




17,776




317,406




56,502


Selling, general and administrative



1,924,293




1,449,545




5,740,158




5,450,282


Impairment expense



917,420




-




917,420




-


Depreciation and amortization



562,143




611,368




1,747,109




1,350,780


Total operating expenses



4,660,333




3,042,020




12,052,802




8,674,904


Loss from operations



(3,917,456)




(1,615,245)




(8,676,652)




(5,462,215)


Other (income) expenses

















Gain on sale of affiliate investment



-




(562,617)




-




(562,617)


Interest (income)



(108)




(46,180)




(17,730)




(46,180)


Interest expense



1,023,165




979,202




3,060,775




2,281,071


Expense incurred in warrant valuation
and conversions



-




49,160




-




49,160


Total other (income) expenses



1,023,057




419,565




3,043,045




1,721,434


Net loss



(4,940,513)




(2,034,810)




(11,719,697)




(7,183,649)


Net loss attributable to non-controlling
interests



(1,647,782)




(728,337)




(3,190,788)




(1,859,069)


Net loss attributable to Parent



(3,292,731)




(1,306,473)




(8,528,909)




(5,324,580)


Other comprehensive income

















Foreign currency translation adjustment



71,067




(32,676)




40,931




(37,873)


Comprehensive loss


$

(3,221,664)



$

(1,339,149)



$

(8,487,978)



$

(5,362,453)



















Net loss attributable to Parent


$

(3,292,731)



$

(1,306,473)



$

(8,528,909)



$

(5,324,580)


Preferred stock dividends



(205,115)




(255,847)




(587,428)




(548,075)


Deemed dividend on down round
feature



(21,738)




(405,324)




(21,738)




(405,324)


Net loss – common shareholders



(3,519,584)




(1,967,644)




(9,138,075)




(6,277,979)


Net loss per common share - basic and
diluted


$

(0.16)



$

(0.13)



$

(0.49)



$

(0.41)


Weighted average number of common
shares outstanding - basic and diluted



22,044,540




15,649,174




18,787,566




15,134,301



 

BioHiTech Global, Inc. and Subsidiaries

Condensed Consolidated Balance Sheets




September 30,
2020



December 31,
2019




(Unaudited)





Assets









Current Assets









Cash


$

4,950,112



$

1,847,526


Restricted cash



1,287,138




1,133,581


Accounts receivable, net of allowance for doubtful accounts of $194,066 and $170,038
as of September 30, 2020 and December 31, 2019, respectively (related entity
$2,227,224 and $1,370,867 as of September 30, 2020 and December 31, 2019,
respectively)



3,311,519




2,155,921


Inventory



627,261




467,784


Prepaid expenses and other current assets



240,939




126,357


Total Current Assets



10,416,969




5,731,169


Restricted cash



2,646,448




2,555,845


Equipment on operating leases, net



1,417,260




1,724,998


HEBioT facility, equipment, fixtures and vehicles, net



36,338,727




37,421,333


Operating lease right of use assets



1,285,292




945,047


License and capitalized MBT facility development costs



8,018,853




8,049,929


Goodwill



58,000




58,000


Other assets



33,749




53,726


Total Assets


$

60,215,298



$

56,540,047



Continued on following page.

 

BioHiTech Global, Inc. and Subsidiaries

Condensed Consolidated Balance Sheets, continued:




September 30,
2020



December 31,
2019




(Unaudited)





Liabilities and Stockholders' Equity









Current Liabilities:









Line of credit, net of financing costs of $2,050 and $20,152 as of September 30, 2020
and December 31, 2019, respectively


$

1,497,950



$

1,479,848


Advances from related parties



935,000




210,000


Accounts payable (related entity $2,021,940 and $2,531,034 as of September 30, 2020
and December 31, 2019, respectively)



6,363,168




4,688,339


Accrued interest payable



627,112




1,148,570


Accrued expenses and liabilities



2,075,576




1,926,965


Deferred revenue



95,331




89,736


Customer deposits



753,046




44,792


Note payable



-




100,000


Senior Secured Note, net of financing costs of $75,767 and unamortized discounts of
$515,719 as of September 30, 2020



4,408,514




-


Current portion of WV EDA Senior Secured Bonds payable



2,860,000




1,390,000


Current portion of long term debt and Payroll Protection Program Loan



261,787




4,605


Total Current Liabilities



19,877,484




11,082,855


Junior note due to related party, net of unamortized discounts of $78,596 and $95,043
as of September 30, 2020 and December 31, 2019, respectively



965,881




949,434


Accrued interest (related party)



1,729,605




1,510,193


WV EDA Senior Secured Bonds payable, net of current portion, and financing costs of
$1,691,516 and $1,792,574 as of September 30, 2020 and December 31, 2019,
respectively



28,448,484




29,817,426


Payroll Protection Program Loan, net of current portion



163,839




-


Senior Secured Note, net of current portion, net of financing costs of $113,268, and
unamortized discounts of $726,242, as of December 31, 2019



-




4,160,490


Note Payable



100,000




-


Non-current lease liabilities



1,231,144




915,170


Long-term debt, net of current portion



4,936




8,201


Total Liabilities



52,521,373




48,443,769


Series A redeemable convertible preferred stock, 333,401 shares designated and issued,
and 125,312 and 145,312 outstanding as of September 30, 2020 and December 31, 2019,
respectively



626,553




726,553


Commitments and Contingencies









Stockholders' Equity









Preferred stock, $0.0001 par value; 10,000,000 shares authorized; 3,209,210 and
3,179,120 designated as of September 30, 2020 and December 31, 2019;
1,936,214 and 1,922,603 issued as of September 30, 2020 and December 31, 2019;
848,292 and 856,181 outstanding as of September 30, 2020 and December 31, 2019:









Series B Convertible preferred stock, 1,111,200 shares designated: 428,333 shares
issued, no shares outstanding as of September 30, 2020 and December 31, 2019



-




-


Series C Convertible preferred stock, 1,000,000 shares designated, 427,500 shares
issued and outstanding as of September 30, 2020 and December 31, 2019



3,050,142




3,050,142


Series D Convertible preferred stock, 20,000 shares designated: 18,850 shares
issued; 17,350 and 18,850 outstanding as of September 30, 2020 and December 31,
2019



1,365,696




1,505,262


Series E Convertible preferred stock, 714,519 shares designated: 714,519 shares
issued, 264,519 outstanding as of September 30, 2020 and December 31, 2019



698,330




698,330


Series F Convertible preferred stock, 30,090 shares designated, and 13,611 shares
issued and outstanding as of September 30, 2020



1,507,408




-


Common stock, $0.0001 par value, 50,000,000 shares authorized, 23,354,130 and
17,300,899 shares issued and outstanding as of September 30, 2020 and December 31,
2019, respectively



2,334




1,730


Additional paid in capital



59,775,963




49,597,059


Accumulated deficit



(61,403,226)




(52,785,242)


Accumulated other comprehensive (loss)



(84,069)




(43,138)


Stockholders' equity attributable to Parent



4,912,578




2,024,143


Stockholders' equity attributable to non-controlling interests



2,154,794




5,345,582


Total Stockholders' Equity



7,067,372




7,369,725


Total Liabilities and Stockholders' Equity


$

60,215,298



$

56,540,047


 

BioHiTech Global, Inc. and Subsidiaries

Condensed Consolidated Statements of Cash Flows (Unaudited)




Nine Months Ended
September 30,




2020



2019


Cash flows from operating activities:









Net loss


$

(11,719,697)




(7,183,649)


Adjustments to reconcile net loss to net cash used in operations:









Depreciation and amortization



1,747,109




1,350,780


Impairment expense



917,420




-


Amortization of operating lease right of use assets



72,402




-


Provision for bad debts



126,119




45,000


Share based employee compensation



1,537,915




741,188


Interest resulting from amortization of financing costs and discounts



419,715




333,782


Share based vendor compensation



297,835




-


Gain on sale of affiliate investment



-




(562,617)


Loss resulting from write-off of proposed MBT site



-




346,654


Warrant modifications



-




49,160


Changes in operating assets and liabilities



(909,507)




(1,137,810)


Net cash used in operating activities



(7,510,689)




(6,017,512)











Cash flow from investing activities:









Purchases of construction in-progress, equipment, fixtures and vehicles



(207,173)




(4,619,883)


Proceeds from sale of investment in affiliate



-




2,250,000


Refund of deposit



5,000




-


MBT facility development costs incurred



(62,949)




(59,013)


MBT facility development costs refunded



-




66,000


Net cash used in investing activities



(265,122)




(2,362,896)











Cash flows from financing activities:









Proceeds from common stock issuance, net of offering costs



8,437,480




3,035,557


Proceeds from the sale of Series F convertible preferred stock units



1,560,450




-


Proceeds from Payroll Protection Program Loan



421,300




-


Proceeds from the sale of Series D convertible preferred stock units



-




1,772,500


Affiliate investment in subsidiary



-




1,400,000


Deferred financing costs incurred



-




(62,151)


Repayments of long-term debt



(3,544)




(6,846)


Related party advances, net



725,000




210,000


Net cash provided by financing activities



11,140,686




6,349,060


Effect of exchange rate on cash (restricted and unrestricted)



(18,129)




12,721


Net change in cash (restricted and unrestricted)



3,346,746




(2,018,627)


Cash - beginning of period (restricted and unrestricted)



5,536,952




9,126,380


Cash - end of period (restricted and unrestricted)


$

8,883,698




7,107,753


 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/biohitech-global-reports-third-quarter-2020-financial-results-301177585.html

SOURCE BioHiTech Global, Inc.


[ Back To TMCnet.com's Homepage ]